IMMUNITRACK ApS

Description of key activities of the company Immunitrack is a commercially active biotech company covering three major business areas including (i) provision of research and development services to pharma and biotechnology companies as well as academic research groups interested in mapping epitopes from cancer, viruses and therapeutics that can elicit an adaptive immune response, (ii) advancement of novel TCR like antibodies (TCRLA) and (iii) development of a novel AI software platform for more accurate predictions of T-cell epitopes. Development in activities and financial matters During the financial year, the entity sold its intangible asstets to US parent company and gaind a profit of t.DKK 141.681. After the sales the entity activity consists of income from the operation of machinery and laboratory equipment and leaseshold. Income or loss from ordinary activities after tax totals t.DKK 110.009 against t.DKK 8.356 last year and the balancesheet at 31. of december 2024 shows an equity of t.DKK 21.212. Management considers the net profit for the year satisfactory. In 2025 the company is expected to merge with Eli Lilly Danmark A/S.